How J&J Hopes To Disrupt India's Diabetes Care Paradigm
Sushobhan Dasgupta, managing director of Johnson & Johnson Medical India, discusses how J&J's new go-to-market strategies are playing out, the role of e-commerce for medical devices in India, and how the company is leveraging its capabilities to provide solutions for the whole diabetic care pathway.
You may also be interested in...
US medtech trade group AdvaMed is prodding the Indian government to harmonize what analysts have called “archaic” regulations governing medical devices with international standards, saying the result would be a win-win for both domestic and foreign companies.
Johnson &Johnson Medical India is implementing a clutch of new go-to-market approaches and managing director Sushobhan Dasgupta expects these to increase the "depth and breadth" of the US multinational's coverage across the country. J&J is the number one medical devices company in India.
Biocon and Mylan press ahead with plans to broaden patient access in the US to biosimilar pegfilgrastim and are enthused with the initial uptake for their trastuzumab biosimilar ahead of more upcoming competition. A mid-2020 US launch for partnered insulin glargine is also on course.